Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immune Reconstitution Inflammatory Syndrome | 3 | 2017 | 17 | 1.130 |
Why?
|
| Measles | 2 | 2016 | 3 | 0.930 |
Why?
|
| Abscess | 3 | 2018 | 79 | 0.910 |
Why?
|
| Travel | 2 | 2016 | 42 | 0.910 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2017 | 30 | 0.900 |
Why?
|
| Bacteremia | 3 | 2017 | 94 | 0.880 |
Why?
|
| Antitubercular Agents | 2 | 2019 | 82 | 0.720 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 107 | 0.710 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 89 | 0.710 |
Why?
|
| HIV Infections | 4 | 2017 | 965 | 0.680 |
Why?
|
| Antiviral Agents | 2 | 2014 | 322 | 0.670 |
Why?
|
| Influenza, Human | 2 | 2012 | 207 | 0.630 |
Why?
|
| Emigration and Immigration | 1 | 2019 | 27 | 0.620 |
Why?
|
| Latent Tuberculosis | 1 | 2019 | 23 | 0.610 |
Why?
|
| Cellulitis | 1 | 2018 | 22 | 0.580 |
Why?
|
| Medication Adherence | 1 | 2019 | 195 | 0.560 |
Why?
|
| Enterococcus faecalis | 1 | 2017 | 12 | 0.540 |
Why?
|
| Rhizopus | 1 | 2016 | 5 | 0.540 |
Why?
|
| Mucormycosis | 1 | 2016 | 10 | 0.530 |
Why?
|
| Aspergillus | 1 | 2016 | 11 | 0.530 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 34 | 0.530 |
Why?
|
| Disease Outbreaks | 2 | 2016 | 115 | 0.520 |
Why?
|
| Aspergillosis | 1 | 2016 | 40 | 0.520 |
Why?
|
| Gonorrhea | 1 | 2018 | 186 | 0.490 |
Why?
|
| Tuberculosis | 2 | 2017 | 295 | 0.480 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2018 | 237 | 0.480 |
Why?
|
| Health Personnel | 1 | 2019 | 363 | 0.480 |
Why?
|
| Staphylococcal Infections | 2 | 2013 | 130 | 0.470 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 221 | 0.460 |
Why?
|
| Bifidobacteriales Infections | 1 | 2014 | 1 | 0.460 |
Why?
|
| Bifidobacterium | 1 | 2014 | 16 | 0.450 |
Why?
|
| Encephalitis, Varicella Zoster | 1 | 2014 | 2 | 0.450 |
Why?
|
| Hallucinations | 1 | 2014 | 16 | 0.450 |
Why?
|
| Acyclovir | 1 | 2014 | 20 | 0.450 |
Why?
|
| Speech Disorders | 1 | 2014 | 17 | 0.440 |
Why?
|
| Diarrhea | 1 | 2014 | 76 | 0.440 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2013 | 2 | 0.440 |
Why?
|
| Homosexuality, Male | 1 | 2014 | 38 | 0.430 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 338 | 0.430 |
Why?
|
| Religion | 1 | 2014 | 30 | 0.430 |
Why?
|
| Clostridium Infections | 1 | 2014 | 49 | 0.430 |
Why?
|
| Travel Medicine | 1 | 2013 | 3 | 0.430 |
Why?
|
| Whooping Cough | 1 | 2013 | 10 | 0.420 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 91 | 0.420 |
Why?
|
| Prostatic Diseases | 1 | 2013 | 9 | 0.410 |
Why?
|
| Subcutaneous Tissue | 1 | 2012 | 14 | 0.400 |
Why?
|
| Drug Eruptions | 1 | 2012 | 15 | 0.400 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2012 | 7 | 0.400 |
Why?
|
| Enterococcus | 1 | 2012 | 10 | 0.390 |
Why?
|
| Liver Failure | 1 | 2012 | 18 | 0.390 |
Why?
|
| Anti-HIV Agents | 2 | 2017 | 154 | 0.390 |
Why?
|
| Virus Shedding | 1 | 2012 | 20 | 0.390 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 65 | 0.390 |
Why?
|
| Oseltamivir | 1 | 2012 | 35 | 0.380 |
Why?
|
| Naltrexone | 1 | 2012 | 89 | 0.380 |
Why?
|
| Endocarditis, Bacterial | 1 | 2012 | 36 | 0.380 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2012 | 14 | 0.380 |
Why?
|
| Anti-Bacterial Agents | 6 | 2018 | 787 | 0.370 |
Why?
|
| Humans | 24 | 2019 | 62934 | 0.370 |
Why?
|
| Pneumonia, Bacterial | 1 | 2012 | 89 | 0.370 |
Why?
|
| Narcotic Antagonists | 1 | 2012 | 135 | 0.360 |
Why?
|
| Cryptococcus neoformans | 1 | 2012 | 148 | 0.340 |
Why?
|
| Aortic Valve | 1 | 2012 | 190 | 0.340 |
Why?
|
| Skin | 1 | 2012 | 377 | 0.320 |
Why?
|
| Genital Neoplasms, Male | 1 | 2009 | 1 | 0.320 |
Why?
|
| Genital Neoplasms, Female | 1 | 2009 | 17 | 0.310 |
Why?
|
| Alphapapillomavirus | 1 | 2009 | 18 | 0.310 |
Why?
|
| Listeriosis | 1 | 2008 | 30 | 0.300 |
Why?
|
| Leprosy | 1 | 2008 | 7 | 0.290 |
Why?
|
| Male | 12 | 2019 | 29594 | 0.290 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 68 | 0.280 |
Why?
|
| Pericarditis | 1 | 2007 | 9 | 0.280 |
Why?
|
| Pericardial Effusion | 1 | 2007 | 21 | 0.280 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 128 | 0.280 |
Why?
|
| Heart Transplantation | 1 | 2008 | 169 | 0.270 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 660 | 0.250 |
Why?
|
| Middle Aged | 8 | 2016 | 17410 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 1594 | 0.240 |
Why?
|
| Female | 10 | 2019 | 32587 | 0.240 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 968 | 0.240 |
Why?
|
| Fatal Outcome | 2 | 2016 | 124 | 0.220 |
Why?
|
| Vaccination | 2 | 2016 | 358 | 0.190 |
Why?
|
| Adult | 5 | 2019 | 16664 | 0.180 |
Why?
|
| Osteoradionecrosis | 1 | 2019 | 4 | 0.160 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2019 | 16 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2018 | 47 | 0.140 |
Why?
|
| Spinal Fusion | 1 | 2019 | 146 | 0.140 |
Why?
|
| Soil Microbiology | 1 | 2016 | 8 | 0.130 |
Why?
|
| Measles Vaccine | 1 | 2016 | 2 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 5413 | 0.120 |
Why?
|
| Aged | 4 | 2014 | 14278 | 0.120 |
Why?
|
| Biopsy | 1 | 2016 | 431 | 0.120 |
Why?
|
| Metronidazole | 1 | 2014 | 9 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2019 | 6556 | 0.120 |
Why?
|
| Herpesvirus 3, Human | 1 | 2014 | 10 | 0.110 |
Why?
|
| Cerebrospinal Fluid | 1 | 2014 | 24 | 0.110 |
Why?
|
| Hospitals, Community | 1 | 2014 | 71 | 0.110 |
Why?
|
| Phenotype | 1 | 2018 | 1196 | 0.110 |
Why?
|
| Aneurysm, Infected | 1 | 2013 | 12 | 0.110 |
Why?
|
| Massachusetts | 1 | 2019 | 2062 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2014 | 579 | 0.100 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2013 | 23 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2018 | 5606 | 0.100 |
Why?
|
| Debridement | 1 | 2012 | 32 | 0.100 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 71 | 0.100 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 97 | 0.100 |
Why?
|
| Syndrome | 1 | 2012 | 179 | 0.100 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2013 | 111 | 0.100 |
Why?
|
| Necrosis | 1 | 2012 | 144 | 0.100 |
Why?
|
| Bronchoscopy | 1 | 2012 | 87 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 143 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2012 | 199 | 0.090 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2012 | 109 | 0.090 |
Why?
|
| Infant | 1 | 2016 | 1638 | 0.090 |
Why?
|
| Acute Coronary Syndrome | 1 | 2013 | 253 | 0.090 |
Why?
|
| Age Factors | 1 | 2014 | 1557 | 0.080 |
Why?
|
| Risk Factors | 2 | 2012 | 5311 | 0.080 |
Why?
|
| United States | 2 | 2013 | 7760 | 0.080 |
Why?
|
| Condylomata Acuminata | 1 | 2009 | 9 | 0.080 |
Why?
|
| Ampicillin | 1 | 2008 | 12 | 0.080 |
Why?
|
| Gastroenteritis | 1 | 2008 | 14 | 0.080 |
Why?
|
| Food Microbiology | 1 | 2008 | 43 | 0.070 |
Why?
|
| Nevirapine | 1 | 2008 | 8 | 0.070 |
Why?
|
| Vancomycin | 1 | 2008 | 39 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 93 | 0.070 |
Why?
|
| Papillomavirus Vaccines | 1 | 2009 | 69 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2009 | 140 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 118 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 203 | 0.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 95 | 0.070 |
Why?
|
| Viral Load | 1 | 2008 | 231 | 0.070 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 123 | 0.070 |
Why?
|
| Pandemics | 1 | 2012 | 668 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 2446 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 82 | 0.040 |
Why?
|
| Oxygen | 1 | 2019 | 316 | 0.030 |
Why?
|
| Pericardiectomy | 1 | 2013 | 1 | 0.030 |
Why?
|
| Pericardiocentesis | 1 | 2013 | 4 | 0.030 |
Why?
|
| Cardiac Tamponade | 1 | 2013 | 15 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 174 | 0.030 |
Why?
|
| Chest Pain | 1 | 2013 | 84 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2013 | 246 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1160 | 0.020 |
Why?
|